Cargando...
Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments
Shilpa Gupta, Estrella Carballido, Mayer FishmanMoffitt Cancer Center and Research Institute, Tampa, FL, USAAbstract: Sipuleucel-T is an autologous cell immunotherapy for castrate-refractory prostate cancer, with US Food and Drug Administration (FDA) approval in asymptomatic or minimally symptomatic...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Dove Medical Press
2011-06-01
|
| Colección: | OncoTargets and Therapy |
| Acceso en línea: | http://www.dovepress.com/sipuleucel-t-for-therapy-of-asymptomatic-or-minimally-symptomatic-cast-a7759 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|